STAT3 and scleroderma: If the approach of leveraging genetic data in evaluating therapies gains traction, the possible signal in CTD/scleroderma is potentially supported by existing meta-analyses data in scleroderma not stratified by presence of PAH, where STAT3 emerges as a risk loci [31].